Canaccord raised the firm’s price target on Neuronetics (STIM) to $8 from $5 and keeps a Buy rating on the shares. The firm said they reported Q4 revenue which was slightly ahead of guidance and management reiterated guidance which was issued in January.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- Neuronetics price target raised to $7 from $3 at Citizens JMP
- 3 Best Stocks to Buy Now, 3/5/2025, According to Top Analysts
- Neuronetics’ Strategic Merger with Greenbrook TMS Fuels Growth and Positive Outlook
- Neuronetics Reports Growth Amid Strategic Acquisitions
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz